Obesity News

It is more appropriate to use BMI as the determinant for metabolic and bariatric surgery in treatment of type 2 diabetes.

During the past 20 years, Endocrine Today has reported on advancements in bariatric and metabolic surgery, including the evolution of the procedure and growth of high-quality clinical trial data documenting efficacy and safety.

The field of cardiology has seen stunning advances in the past several years: HF, dyslipidemia and cardiomyopathy are just three of the disorders in which there have been recent practice-changing therapeutic innovations.

School-aged children gained more excess weight during the COVID-19 pandemic compared with the year prior, with a greater degree of weight gain observed among Black and Hispanic children, according to data published in Obesity.

The CDC released extended charts so clinicians can assess the growth and treatment of children and adolescents with severe obesity.

Obesity was not a universal phenotype among children with type 2 diabetes, despite being an important risk factor, according to a systematic review and meta-analysis published in JAMA Network Open.

Results from a meta-analysis underscored the need to improve understanding of nonalcoholic fatty liver disease burden and management in at-risk individuals who are overweight and obese.

Short-term time-restricted eating resulted in no changes in sex steroid levels but was associated with a decrease in dehydroepiandrosterone for premenopausal and postmenopausal women with obesity, according to study data.

Among adults with obesity, bariatric surgery conferred greater weight and BMI reductions than GLP-1 receptor agonist therapy, but effects on HbA1c were similar between the two modalities, researchers reported.

Primary care provider referral to an automated weight-loss program resulted in significantly increased weight loss at 6 and 12 months vs. usual care, according to study findings published in Obesity.